Literature DB >> 7679668

Effect of rest interval on tumor and normal tissue response--a report of phase III study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG-8502)

W J Spanos1, C A Perez, S Marcus, C A Poulter, R L Doggett, A D Steinfeld, P W Grigsby.   

Abstract

From August 1985 through September 1989, 284 patients with advanced pelvic malignancies were entered into a trial (RTOG 8502) of palliative split course radiation (4440 cGy in three courses of 1480 cGy/2 days/4 fractions with a rest of 2-4 weeks between courses). The initial 148 patients were part of a Phase II acceptable response rate and minimal acute or late toxicity (IJRBP 17:659-662, 1989). The present analysis is a report of the subsequent 136 patients randomized between rest intervals of 2 weeks versus 4 weeks to determine if length of rest would influence tumor response or patient toxicity. The patients were stratified for performance status (Karnofsky Performance Status) and histology. The patients were evenly matched for age and sex. There was a trend toward increased acute toxicity incidence in patients with shorter rest interval (5/68 versus 0/68; p = .07). Late toxicity was not significantly different between the two groups. Decreasing the interval between courses did not result in a significant improvement in tumor response (CR+PR = 34% vs. 26%, p = n.s.). More patients in the 2 week groups completed all three courses (72% vs. 63%). Not surprisingly, patients completing cell three courses had a significantly higher overall response rate than for patients completing less than three courses (42% vs. 5%) and higher complete response rate (17% vs. 1%). A multivariate analysis indicated performance status as the significant predictor for number of courses completed. For Karnofsky Performance Status greater than or equal to 80, the survival at 12 months was 40% for the 2 week interval and 25% for the 4 week interval. Performance status and histology were the only significant variables in a multivariate analysis of survival.

Entities:  

Mesh:

Year:  1993        PMID: 7679668     DOI: 10.1016/0360-3016(93)90059-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jim N Rose; Juanita M Crook
Journal:  Ther Adv Urol       Date:  2015-06

2.  Radiation therapy oncology group gynecologic oncology working group: comprehensive results.

Authors:  David K Gaffney; Anuja Jhingran; Lorraine Portelance; Akila Viswanathan; Tracey Schefter; Joanne Weidhaas; William Small
Journal:  Int J Gynecol Cancer       Date:  2014-06       Impact factor: 3.437

3.  Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment.

Authors:  Gabriella Macchia; Francesco Deodato; Savino Cilla; Francesco Legge; Vito Carone; Vito Chiantera; Vincenzo Valentini; Alessio Giuseppe Morganti; Gabriella Ferrandina
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

4.  COVID-19: Global radiation oncology's targeted response for pandemic preparedness.

Authors:  Richard Simcock; Toms Vengaloor Thomas; Christopher Estes; Andrea R Filippi; Matthew A Katz; Ian J Pereira; Hina Saeed
Journal:  Clin Transl Radiat Oncol       Date:  2020-03-24

5.  Palliative Radiation Therapy for Oncologic Emergencies in the Setting of COVID-19: Approaches to Balancing Risks and Benefits.

Authors:  Divya Yerramilli; Amy J Xu; Erin F Gillespie; Annemarie F Shepherd; Kathryn Beal; Daniel Gomez; Josh Yamada; C Jillian Tsai; T Jonathan Yang
Journal:  Adv Radiat Oncol       Date:  2020-04-08

6.  Definitive vs palliative pelvic radiation for patients with newly diagnosed stage IVB cervical cancer treated with bevacizumab - An exploratory study.

Authors:  Rachel L Wiley; Ioana L Bondre; Randa Jalloul; Ann H Klopp; Jolyn S Taylor; Lois M Ramondetta
Journal:  Gynecol Oncol Rep       Date:  2022-03-23

7.  A "SHort course Accelerated RadiatiON therapy" (SHARON) During and Beyond the COVID-19 Pandemic.

Authors:  Alessio G Morganti; Gabriella Macchia; Francesco Cellini; Francesco Deodato; Alice Zamagni; Giambattista Siepe; Milly Buwenge
Journal:  Front Oncol       Date:  2022-02-23       Impact factor: 6.244

8.  Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model.

Authors:  Francesco Cellini; Rossella Di Franco; Stefania Manfrida; Valentina Borzillo; Ernesto Maranzano; Stefano Pergolizzi; Alessio Giuseppe Morganti; Vincenzo Fusco; Francesco Deodato; Mario Santarelli; Fabio Arcidiacono; Romina Rossi; Sara Reina; Anna Merlotti; Barbara Alicja Jereczek-Fossa; Angelo Tozzi; Giambattista Siepe; Alberto Cacciola; Elvio Russi; Maria Antonietta Gambacorta; Marta Scorsetti; Umberto Ricardi; Renzo Corvò; Vittorio Donato; Paolo Muto; Vincenzo Valentini
Journal:  Radiol Med       Date:  2021-09-27       Impact factor: 3.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.